These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17431340)

  • 1. [Translational research in patients with lung cancer--clinical application of NKT cell immunotherapy].
    Motohashi S
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):550-3. PubMed ID: 17431340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.
    Motohashi S; Kobayashi S; Ito T; Magara KK; Mikuni O; Kamada N; Iizasa T; Nakayama T; Fujisawa T; Taniguchi M
    Int J Cancer; 2002 Nov; 102(2):159-65. PubMed ID: 12385012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells.
    Akutsu Y; Nakayama T; Harada M; Kawano T; Motohashi S; Shimizu E; Ito T; Kamada N; Saito T; Matsubara H; Miyazawa Y; Ochiai T; Taniguchi M
    Jpn J Cancer Res; 2002 Apr; 93(4):397-403. PubMed ID: 11985789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells.
    Okai M; Nieda M; Tazbirkova A; Horley D; Kikuchi A; Durrant S; Takahashi T; Boyd A; Abraham R; Yagita H; Juji T; Nicol A
    Vox Sang; 2002 Oct; 83(3):250-3. PubMed ID: 12366768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.
    Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M
    J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.
    Fujii S; Shimizu K; Steinman RM; Dhodapkar MV
    J Immunol Methods; 2003 Jan; 272(1-2):147-59. PubMed ID: 12505720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.
    Chang DH; Osman K; Connolly J; Kukreja A; Krasovsky J; Pack M; Hutchinson A; Geller M; Liu N; Annable R; Shay J; Kirchhoff K; Nishi N; Ando Y; Hayashi K; Hassoun H; Steinman RM; Dhodapkar MV
    J Exp Med; 2005 May; 201(9):1503-17. PubMed ID: 15867097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.
    Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H
    Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.
    Nagato K; Motohashi S; Ishibashi F; Okita K; Yamasaki K; Moriya Y; Hoshino H; Yoshida S; Hanaoka H; Fujii S; Taniguchi M; Yoshino I; Nakayama T
    J Clin Immunol; 2012 Oct; 32(5):1071-81. PubMed ID: 22534863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
    Shimizu K; Goto A; Fukui M; Taniguchi M; Fujii S
    J Immunol; 2007 Mar; 178(5):2853-61. PubMed ID: 17312129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.
    Nicol AJ; Tazbirkova A; Nieda M
    Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
    Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
    Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
    J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells.
    Kawano T; Nakayama T; Kamada N; Kaneko Y; Harada M; Ogura N; Akutsu Y; Motohashi S; Iizasa T; Endo H; Fujisawa T; Shinkai H; Taniguchi M
    Cancer Res; 1999 Oct; 59(20):5102-5. PubMed ID: 10537282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
    Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
    J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
    Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N
    J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.